Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.

Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB.

Thyroid. 2014 May;24(5):820-5. doi: 10.1089/thy.2013.0362. Epub 2014 Jan 29.

2.

Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.

Rosário PW, Calsolari MR.

Thyroid. 2014 May;24(5):826-31. doi: 10.1089/thy.2013.0479. Epub 2014 Jan 24.

PMID:
24283207
3.

Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.

Scheffel RS, Zanella AB, Dora JM, Maia AL.

Thyroid. 2016 Nov;26(11):1623-1629. Epub 2016 Sep 22.

PMID:
27549175
4.

Radioiodine remnant ablation in low-risk differentiated thyroid cancer.

Saengsuda Y.

J Med Assoc Thai. 2013 May;96(5):614-24.

PMID:
23745318
5.

Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.

Aldawish M, Jha N, McEwan AJ, Severin D, Ghosh S, Morrish DW.

Endocr Res. 2014;39(4):157-63. doi: 10.3109/07435800.2013.865211. Epub 2014 Jan 24.

PMID:
24460082
6.

Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.

Welsh L, Powell C, Pratt B, Harrington K, Nutting C, Harmer C, Newbold K.

J Clin Endocrinol Metab. 2013 May;98(5):1819-25. doi: 10.1210/jc.2013-1197. Epub 2013 Mar 14.

PMID:
23493434
7.

Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.

Jeong JH, Kong EJ, Jeong SY, Lee SW, Cho IH, Ah Chun K, Lee J, Ahn BC.

Nucl Med Commun. 2017 Mar;38(3):228-233. doi: 10.1097/MNM.0000000000000636.

PMID:
27984538
8.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137. Epub 2013 Apr 26.

PMID:
23626005
9.

Clinical outcome in differentiated thyroid carcinoma and microcarcinoma.

Lupoli R, Cacciapuoti M, Tortora A, Barba L, Verde N, Romano F, Vastarella M, Fonderico F, Masone S, Milone M, Lupoli G, Lupoli GA.

Int J Surg. 2014;12 Suppl 1:S148-51. doi: 10.1016/j.ijsu.2014.05.024. Epub 2014 May 22.

10.

Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?

Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I.

Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.

PMID:
23158181
11.

Remnant uptake as a postoperative oncologic quality indicator.

Schneider DF, Ojomo KA, Chen H, Sippel RS.

Thyroid. 2013 Oct;23(10):1269-76. doi: 10.1089/thy.2012.0451. Epub 2013 Jul 17.

12.

Treatment for microcarcinoma of the thyroid--clinical experience.

Küçük NO, Tari P, Tokmak E, Aras G.

Clin Nucl Med. 2007 Apr;32(4):279-81.

PMID:
17413573
13.

The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB.

Cancer. 1998 Jan 15;82(2):375-88.

PMID:
9445196
14.

Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.

Byeon HK, Holsinger FC, Tufano RP, Chung HJ, Kim WS, Koh YW, Choi EC.

Ann Surg Oncol. 2014 Nov;21(12):3872-5. doi: 10.1245/s10434-014-3896-y. Epub 2014 Sep 17.

PMID:
25227305
15.

Low activity versus high activity: noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension.

Wang C, Zhao T, Li H, Gao W, Lin Y.

Nucl Med Commun. 2017 May;38(5):366-371. doi: 10.1097/MNM.0000000000000666.

PMID:
28362717
16.

Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin.

Zhang Y, Liang J, Yang X, Yang K, Lin Y.

Nucl Med Commun. 2015 Jun;36(6):553-9. doi: 10.1097/MNM.0000000000000296.

PMID:
25793928
17.

A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.

Ben Ghachem T, Yeddes I, Meddeb I, Bahloul A, Mhiri A, Slim I, Ben Slimene MF.

Eur Arch Otorhinolaryngol. 2017 Feb;274(2):655-660. doi: 10.1007/s00405-016-4111-5. Epub 2016 May 25.

PMID:
27225282
18.

Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.

Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, Belardini V, Brianzoni E, Pacini F.

Eur J Endocrinol. 2013 Jun 1;169(1):23-9. doi: 10.1530/EJE-12-0954. Print 2013 Jul.

19.

Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.

Mitchell AL, Gandhi A, Scott-Coombes D, Perros P.

J Laryngol Otol. 2016 May;130(S2):S150-S160.

20.

Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.

Momesso DP, Vaisman F, Caminha LS, Pessoa CH, Corbo R, Vaisman M.

J Endocrinol Invest. 2014 Jan;37(1):57-64. doi: 10.1007/s40618-013-0015-z. Epub 2014 Jan 8.

PMID:
24464451

Supplemental Content

Support Center